CPRX (Catalyst Pharmaceuticals) Insider Ownership: 8.07 % (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPRX Catalyst Pharmaceuticals Inc CPRX
70 GF Score
Price $31.49
GF Value $25.01
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals Insider Ownership?

Catalyst Pharmaceuticals CPRX +0.02% 70 Insider Ownership is 8.07 % as of Sep. 02, 2026. GuruFocus rates CPRX with a GF Score™ of 70/100 and a GF Value™ of $25.01 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Catalyst Pharmaceuticals's insider ownership is 8.07%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Catalyst Pharmaceuticals's Institutional Ownership is 90.04%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Catalyst Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 94.48%.

Catalyst Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Catalyst Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals Insider Ownership Chart

Catalyst Pharmaceuticals Historical Data

The historical data trend for Catalyst Pharmaceuticals can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 7.91 7.91 8.04 8.11 8.11 8.11 8.09 8.09 8.07 8.07
CPRX
70GF Score
Catalyst Pharmaceuticals Inc CPRX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catalyst Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 8.07 % mean?
Catalyst Pharmaceuticals (CPRX) has a Insider Ownership of 8.07 % as of Sep. 02, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Catalyst Pharmaceuticals and its competitors.
Is Catalyst Pharmaceuticals' Insider Ownership too high?
Catalyst Pharmaceuticals' current Insider Ownership is 8.07 %. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Insider Ownership compare to PBLS and ELVN?
Catalyst Pharmaceuticals' Insider Ownership of 8.07 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current Insider Ownership is 8.07 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.01, compared to a current price of $31.49 — trading 25.9% above its estimated fair value. The current Insider Ownership is 8.07 %. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current Insider Ownership is 8.07 % as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of $31.49 is trading 25.9% above its estimated GF Value™ of $25.01. GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for CPRX:

  • Insider Ownership: 8.07 %
  • GF Value™: $25.01 vs. price of $31.49 (25.9% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catalyst Pharmaceuticals Business Description

Other Exchanges CN2:Germany
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score

Get the complete analysis for CPRX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.49
Price
$25.01
GF Value